Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of 252 patients with sytemic lupus erythematosus with inactive and active disease at inclusion

From: Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)

Characteristics All (N = 252) Inactivea (N = 127) Activea (N = 125) p-value
Sex, women/men (%) 207/45 (82/18) 104/23 (82/18) 103/22 (82/18) 1.00
Age, median [IQR], years 43 [32–57] 45 [32–59] 42 [32–55] 0.23
Body mass index, median [IQR], kg/m2 24.1 [21.2–27.4] 24.4 [22.0–28.5] 24.0 [20.9–26.7] 0.07
Smoking, no (%) 46 (18) 15 (12) 31 (25) <0.01
Disease duration, median [IQR], years 6.2 [2.6–14.3] 6.0 [2.9–12.8] 6.6 [2.3–15.1] 0.45
ACR criteria
 Malar rash, no (%) 92 (37) 42 (33) 50 (40) 0.30
 Discoid rash, no (%) 46 (18) 28 (22) 18 (14) 0.14
 Photosensitivity, no (%) 121 (48) 58 (46) 63 (50) 0.53
 Nasopharyngeal ulcers, no (%) 70 (28) 35 (28) 35 (28) 1.00
 Arthritis, no (%) 173 (69) 83 (65) 90 (72) 0.28
 Pleuritis, no (%) 58 (23) 26 (21) 32 (26) 0.45
 Pericarditis, no (%) 44 (18) 23 (18) 21 (17) 0.87
 Renal disorder, no (%) 90 (36) 39 (31) 51 (41) 0.12
 Seizures, no (%) 12 (5) 4 (3) 8 (6) 0.25
 Psychosis, no (%) 13 (5) 6 (5) 7 (6) 0.78
 Hematologic disorder, no (%) 155 (62) 73 (58) 82 (66) 0.20
 Antinuclear antibodies positive, no (%) 246 (98) 125 (98) 121 (97) 0.44
 Anti-Sm antibody positive, no (%) 38 (15) 13 (10) 25 (20) 0.035
 Anti-dsDNA antibodies positive, no (%) 150 (60) 68 (54) 82 (66) 0.055
 Anti-phospholipid antibodies positive, no (%) 108 (43) 55 (43) 53 (42) 0.90
Laboratory values
 Haemoglobin, median [IQR], g/L 130 [117–137] 131 [122–138] 128 [113–135] 0.011
 Leukocytes, median [IQR], G/L 5.9 [4.5–7.7] 5.6 [4.3–7.5] 6.2 [4.6–8.35] 0.12
 Platelets, median [IQR], G/L 238 [189–294] 240 [189–285] 236 [185–303] 0.97
 Plasma creatinin, median [IQR], μmol/L 70 [61–87] 70 [61–86] 70 [61–92] 0.64
 Serum albumin, median [IQR], g/L 39.2 [36.6–42.0] 40.1 [38.8–42.7] 38 [35.0–40.3] <0.0001
 Erythrocyte sedimentation rate, median [IQR], mm/1st hour 12 [6–29] 10 [5–26] 14 [7–34] 0.013
Disease activity and damage
 Physician global assesment, median [IQR] 0 [0–1] 0 [0–1] 1 [0–1.25] <0.0001
 SELENA-SLEDAI, median [IQR] 3 [0.25–8] 1 [0–2] 8 [4–12] <0.0001
Treatment
 Oral glucocorticosteroids, no (%) 141 (56.0) 55 (43.3) 85 (68) <0.0001
 Daily prednisone equivalent, median [IQR], mg 7.5 [5–12] 5 [5–7.5] 9 [5–20] <0.0001
 Antimalarials, no (%) 178 (71) 91 (71) 87 (70) 0.68
 Immunosuppressants, no (%) 120 (48) 55 (43) 65 (52) 0.21
  1. SD Standard deviation, IQR Interquartile range, NS non significant, SELENA-SLEDAI Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA), SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index
  2. aInactive disease at baseline was defined by a SELENA-SLEDAI < 4 and active disease by a SELENA-SLEDAI ≥ 4